Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Advanced Cutaneous Squamous Cell Carcinoma Clinical Trial

Official title:
A Phase Ib/II, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of IBI318 in Participants With Advanced Cutaneous Squamous Cell Carcinoma.

Status Terminated

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of IBI318 (anti-PD-1/PD-L1) in adult participants with metastatic (nodal or distant) cutaneous squamous cell carcinoma (CSCC), or unresectable locally advanced CSCC that is not amenable to surgery and/or radiation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Advanced Cutaneous Squamous Cell Carcinoma
Carcinoma
Carcinoma, Squamous Cell

Clinical Trial Details

NCT number	NCT04611321
Study type	Interventional
Source	Innovent Biologics (Suzhou) Co. Ltd.
Contact
Status	Terminated
Phase	Phase 1/Phase 2
Start date	December 1, 2020
Completion date	March 10, 2023

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03834233` - Nivolumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma	Phase 2
Active, not recruiting	`NCT04050436` - Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer	Phase 2
Active, not recruiting	`NCT04807777` - Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma	Phase 2
Completed	`NCT02760498` - Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma	Phase 2